<DOC>
	<DOCNO>NCT01767402</DOCNO>
	<brief_summary>The purpose study examine safety , reactogenicity immunogenicity GlaxoSmithKline ( GSK ) Biologicals candidate pneumococcal vaccine contain PhtD healthy elderly population age 18-45 year age .</brief_summary>
	<brief_title>Study Evaluate Safety , Reactogenicity Immunogenicity Pneumococcal Protein PhtD Vaccine Healthy Adults</brief_title>
	<detailed_description>The safety profile PhtD vaccine assess comparison comparator vaccine ( Pneumovax 23TM ) . In order increase immune response vaccination , novel adjuvant system also examine .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female , include , 18 45 year time first vaccination . Written inform consent obtain subject . Free obvious health problem establish medical history clinical examination enter study . If subject female , must nonchildbearing potential , i.e. , either surgically sterilize one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period participation another pharmaceutical/vaccine study . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Use anticoagulant . Planned administration/ administration vaccine foreseen study protocol within 2 week first dose vaccine . Previous vaccination Streptococcus pneumoniae . Bacterial pneumonia within 3 year prior 1st vaccination . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine . Current serious neurologic mental disorder . Inflammatory process know chronic active infection . All malignancy ( exclude nonmelanic skin cancer ) lymphoproliferative disorder diagnose treat actively past 5 year . History administration experimental vaccine contain 3deacylated Monophosphoryl Lipid A ( MPL ) Quillaja saponaria 21 ( QS21 ) . Acute disease time enrolment . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e. , Oral temperature &lt; 37.5°C Axillary temperature &lt; 37.5°C . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , discretion investigator . Pregnant lactate female . History chronic alcohol consumption and/or intravenous drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal Infections</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>PhtD vaccine</keyword>
	<keyword>Healthy adult</keyword>
	<keyword>Reactogenicity</keyword>
</DOC>